TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Response rate of SARS-CoV-2-specific B cells in peripheral blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response rate of SARS-CoV-2-specific neutralizing antibodies in serum samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response rate of SARS-CoV-2-specific CD4+ and CD8+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of life related to health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Height gain, SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height gain in cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of prevalence of maternal prenatal depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of prevalence of maternal postpartum depression in the first year after delivery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Freezing of Gait Questionnaire (FOGQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean carbon dioxide partial pressure-level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Equipment Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of subclinical signs of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: NRS score during mobility assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skin wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: IKDC score of the knee
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cervical dilation at time of epidural administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic yield of invasive angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in instances of burnout for hospital staff due to the Peer Resilience Champion intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in instances of burnout for hospital staff due to the Enriched Feedback Survey intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of Glucose Measurements within Target Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chronic graft versus host disease (GVHD)-free, relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Ventricular fibrillation (VF) detection time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular Capture Management accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change of plasma concentration of Tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Uropathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Patients With Confirmed Complete Responses (CR) and Partial Responses (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of 50% or More of Neck and Arm Pain NRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active PIP joint range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lateral stability in coronal plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Withdrawal Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Score for Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Headache Disability Inventory (HDI)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Changes of Migraine Specific Quality of Life Questionnaire version 2.1 (MSQv2.1)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes of Depression, Anxiety and Stress Scale (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ECG and echocardiography evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Laryngospasm
Endpoint domain: Adverse events/effects
Primary endpoint: Combined Ocular Surface Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of non-operated on patients with negative viability markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: residual mitral regurgitation (MR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hospitalization for heart failure
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Maintenance of the major curvature ≤ 50 degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Concentration of Etonogestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: SEMS dislocation in cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: long-term treatment effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade of inhibition of PI3K/mTOR pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of serious and non-serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Scenario-execution-group test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total ephedrine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Western Ontario Rotator Cuff (WORC) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Gartland Classification of X-ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cell surface expression of TRAIL receptor-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of severe bacterial infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean change in Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Significant Unfavorable ECGs at Week 12
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiovascular Adverse Events Reported During Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: Asthma Exacerbations: Worsening of Asthma Requiring Emergency Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Change in psychological health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the number of participants that complete the therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Death by any cause
Endpoint domain: Mortality/survival
Primary endpoint: Non-Fatal DVT, PE, and CVST, and VTE-Related-Death
Endpoint domain: Mortality/survival
Primary endpoint: Adjudicated Major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Number of VZV DNA copies per clinical sample collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of HSV DNA copies per clinical sample collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of actin DNA copies per clinical sample collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Grade 2 or Greater Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious adverse drug reactions including major hypoglycaemic events
Endpoint domain: Adverse events/effects
Primary endpoint: I-FABP levels in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Effect of anti-viral therapy on insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety, efficacy and tolerability of Pegasys and Copegus
Endpoint domain: Adverse events/effects
Primary endpoint: VZV specific serum conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VZV specific serum geometric mean titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VZV specific serum geometric mean fold increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Unified Parkinson's Disease Rating Scale (UPDRS) III (motor score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: sensitivity of Klemetti Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of Klemetti Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Oxymetazoline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Tetracaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of PBBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half Life of Oxymetazoline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half Life of Tetracaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half Life of PBBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three-dimensional gait analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selective motor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of signet ring cell carcinoma foci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Clinically Significant Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wheelchair-related Falls
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in attack frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement of hearing loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with HbA1c<48 mmol/mol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of lipid peroxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of EDP 305
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of EDP 305
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of EDP 305
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CL/F of EDP 305
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve from 0 to the last measurable concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve from 0 to infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of NUV-422
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life 1 month after laparoscopic removal of Essure®
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: High Frequency Heart Rate Variability (HF-HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality rates from COVID 19
Endpoint domain: Mortality/survival
Primary endpoint: Health related quality of life - Short Form 12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Immediate Vaccine Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative inequality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sufficient treatment dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of antibody formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disappearance of watering of the eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term excess mortality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with regular gynecological follow-up and cervical screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bidigital Vaginal Palpation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Prolonged Abstinence at 6 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-reported Prolonged Abstinence at 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of major bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite Sudden Cardiac Death Event
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Tolerated Dose (MTD) in Milligrams (mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Stable Disease In Response to Study Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Serum Concentration of Bevacizumab (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-time Curve of Bevacizumab (ABC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration- Time Curve of Bevacizumab (ABC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total plasma concentrations of inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage change in LDL-C levels from baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of subjects with LDL-C levels of <100 mg/dL at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression-free rate at Day 84 post randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal standard uptake value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients in virological failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in break fall competence/skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Participants' Falls Efficacy after 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immunogenicity as measured by Anti-H7N7 antibody and seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of vaccine-related reactogenicity events (REs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of other adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: changes in symptom scores on the Edmonton assessment scale (ESAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BICR-RFS
Endpoint domain: Mortality/survival
Primary endpoint: Apgar 1st minute score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apgar 5th minute score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for neonatal intensive care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in plasma total cysteine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binary in-segment angiographic restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Neurocognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Monthly Mean NRS for Endometriosis Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clotting abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Myocardial damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Faecal bile acids retention values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: SeHCAT retention values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Log Transformed Area Under the Curve of 17-hydroxyprogesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ICG Fluorescence Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission defined as HRSD-17 total score ≤ 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faecal incontinence assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Air Microemboli Registered Over the Middle Cerebral Arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With <=Grade I Gas Emboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Pathologic Complete Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density-Total Body
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density-lumbar Spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of injection-site adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: non serious systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in immune-associated transcripts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: patients' autonomy
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Average time for self-catheterisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Confirmed Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries arresting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Excessive Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of Post-procedure Blood Loss Measured in mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to OZURDEX® Re-Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Pharmacokinetics of HALAVEN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Magnitude of drop in Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anaesthesia and procedural related time intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Activation of proteins in monocyte membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete tumour response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Facial Entropy Score From Baseline [Off Dopamine Medication]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Facial Entropy Score From Baseline [On Dopamine Medication]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Bioequivalence of particle sizes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: value of PetCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Grading of Efficacy Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability Evaluations
Endpoint domain: Adverse events/effects
Primary endpoint: Quantity of THC in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of endogenous metabolites (plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes